Patient Native Causal AI for Drug Discovery
South San Francisco, California
Synlico is a patient-native causal AI biotech building a generative causal discovery and inference platform SynCausal(TM) that learns directed gene causal graphs from primary patient scRNA-seq at scale. Synlico tackles a core bottleneck: drug R&D decisions and human disease biology remain correlation-led and often fail to translate across heterogeneous patients and microenvironments. Synlico's SynCausal(TM) identifies upstream disease drivers, quantifies downstream effects of genes and pathways, and returns predicted intervention effects and mechanistic rationales. Its advantage is compounded by Synlico’s large, diverse and high-quality patient native causal-grade context data infrastructure
Remote · Canada
The scientist will design state-of-the-art generative models for biological systems at the cellular level. They will collaborate with bioinformatics and causal teams to lead innovation initiatives and incorporate new technologies.